Alanine aminotransferase and gamma-glutamyl transferase are associated with the metabolic syndrome but not with angiographically determined coronary atherosclerosis

Clinica Chimica Acta

Volumn 397, Issue 1-2, 2008, Pages 82-86

  Saely, Christoph H ^a,b,c   Vonbank, Alexander ^a,b,c   Rein, Philipp ^a,b,c   Woess, Magdalena ^a   Beer, Stefan ^a,b,c   Aczel, Stefan ^a,b   Jankovic, Vlado ^a   Boehnel, Christian ^a   Risch, Lorenz ^a   Drexel, Heinz ^a,b,c  

^a Vorarlberg Institute for Vascular Investigation and Treatment VIVIT   (Austria)

^b ACADEMIC TEACHING HOSPITAL FELDKIRCH   (Austria)

^c University for Human Sciences   (Liechtenstein)

Author keywords

Alanine aminotransferase; Aspartate aminotransferase; Atherosclerosis; Coronary angiography; Gamma glutamyl transferase; Liver enzymes; Metabolic syndrome

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ANGIOCARDIOGRAPHY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE ASSOCIATION; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL;

AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; LIVER; MALE; METABOLIC SYNDROME X; MIDDLE AGED;

EID: 51549091563     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2008.07.024     Document Type: Article

References (35)

1. Schindhelm R.K., Dekker J.M., Nijpels G., et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 191 (2007) 391-396
2. Ruttmann E., Brant L.J., Concin H., Diem G., Rapp K., and Ulmer H. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 112 (2005) 2130-2137
3. Meisinger C., Doring A., Schneider A., and Lowel H. Serum gamma-glutamyltransferase is a predictor of incident coronary events in apparently healthy men from the general population. Atherosclerosis 189 (2006) 297-302
4. Lee D.S., Evans J.C., Robins S.J., et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 27 (2007) 127-133
5. Grundy S.M. Gamma-glutamyl transferase: another biomarker for metabolic syndrome and cardiovascular risk. Arterioscler Thromb Vasc Biol 27 (2007) 4-7
6. Clark J.M., Brancati F.L., and Diehl A.M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98 (2003) 960-967
7. Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabet Med 24 (2007) 1-6
8. Bugianesi E., Gastaldelli A., Vanni E., et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 48 (2005) 634-642
9. Marchesini G., Brizi M., Bianchi G., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50 (2001) 1844-1850
10. Angelico F., Del Ben M., Conti R., et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 90 (2005) 1578-1582
11. Lee M.Y., Koh S.B., Koh J.H., et al. Relationship between gamma-glutamyltransferase and metabolic syndrome in a Korean population. Diabet Med (2008)
12. Saely C.H., Aczel S., Marte T., Langer P., Hoefle G., and Drexel H. The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. J Clin Endocrinol Metab 90 (2005) 5698-5703
13. Fuster V., Badomon L., Badimon J.J., and Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 326 (1992) 242-250
14. Fuster V., Badomon L., Badimon J.J., and Chesebro J.H. he pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 326 (1992) 310-318
15. Scanlon P.J., Faxon D.P., Audet A.M., et al. ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol 33 (1999) 1756-1824
16. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572
17. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15 (1998) 539-553
18. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
19. The IDF consensus worldwide definition of the metabolic syndrome [article online], 2005. Available from http://www.idf.org/webdata/docs/metac_syndrome_def.pdf. Accessed on 24 June 2008.
20. Drexel H., Amann F.W., Beran J., et al. Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis. Circulation 90 (1994) 2230-2235
21. Saely C.H., Koch L., Schmid F., et al. Lipoprotein(a), type 2 diabetes and vascular risk in coronary patients. Eur J Clin Invest 36 (2006) 91-97
22. Kotronen A., and Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 28 (2008) 27-38
23. Neuschwander-Tetri B.A. Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci 330 (2005) 326-335
24. Adibi P., Sadeghi M., Mahsa M., Rozati G., and Mohseni M. Prediction of coronary atherosclerotic disease with liver transaminase level. Liver Int 27 (2007) 895-900
25. Eckel R.H., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet 365 (2005) 1415-1428
26. Seppala-Lindroos A., Vehkavaara S., Hakkinen A.M., et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 87 (2002) 3023-3028
27. Adiels M., Taskinen M.R., Packard C., et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 49 (2006) 755-765
28. Malmstrom R., Packard C.J., Caslake M., et al. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 40 (1997) 454-462
29. Targher G., Bertolini L., Scala L., Poli F., Zenari L., and Falezza G. Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clin Endocrinol (Oxf) 61 (2004) 700-703
30. Bahcecioglu I.H., Yalniz M., Ataseven H., et al. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis. Hepatogastroenterology 52 (2005) 1549-1553
31. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 (2004) 1387-1395
32. Kotronen A., Westerbacka J., Bergholm R., Pietilainen K.H., and Yki-Jarvinen H. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 92 (2007) 3490-3497
33. Pratt D.S., and Kaplan M.M. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 342 (2000) 1266-1271
34. Luyckx F.H., Lefebvre P.J., and Scheen A.J. Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab 26 (2000) 98-106
35. Belfort R., Harrison S.A., Brown K., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355 (2006) 2297-2307